Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Jagsonpal aims for mid-to-high teen growth in revenue, targeting to outgrow the Indian pharma market by 1.5x. Jagsonpal Pharmaceuticals targets mid-to-high teen revenue growth, aiming to outgrow the Indian pharma industry by 1.5x.
From Jagsonpal Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Jagsonpal aims for mid-to-high teen growth in revenue, targeting to outgrow the Indian pharma market by 1.5x.
- Focus on organic growth through power brands like Indocap, Maintane, Endoreg, Pru, and Eukroma, which are outperforming their therapy markets.
- The company is enhancing productivity, operational excellence, and improving margins while growing sales.
- Expansion into the hospital segment via the acquisition of Aequitas Healthcare, targeting Rs.100 crores revenue from Aequitas by FY28-29.
- Cross-selling Jagsonpal’s branded products into the hospital network to drive incremental value.
- Pipeline includes launching innovative products with potential for first-in-India or breakthrough molecules expected to enhance premiumization.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jagsonpal Pharmaceuticals has been focusing on disciplined capital allocation balancing organic and inorganic growth.
- Over the last four years, the company generated over Rs.250 crores of operating cash used for strategic acquisitions like Yash Pharma (over Rs.90 crores).
- Recently acquired 85% stake in Aequitas Healthcare for Rs.20.8 crores to enter and expand in the hospital segment.
- Integration planning for Aequitas underway with expected synergies over the next 36 months.
- The company continues to evaluate value-accretive inorganic opportunities for growth.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Jagsonpal Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹64 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q1 FY27 results?
Jagsonpal aims for mid-to-high teen growth in revenue, targeting to outgrow the Indian pharma market by 1.5x. Jagsonpal Pharmaceuticals targets mid-to-high teen revenue growth, aiming to outgrow the Indian pharma industry by 1.5x.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals has been focusing on disciplined capital allocation balancing organic and inorganic growth.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.